Press Room

EFGC NEWS

EFGC’s Studio E artwork on display at American Epilepsy Society Annual Meeting
Published on December 2, 2011

BALTIMORE–(BUSINESS WIRE)–Today, Lundbeck announced its Studio E: The Epilepsy Art Therapy Program will be made available in 21 cities next year through partnerships with local Epilepsy Foundation affiliates across the country. Earlier this year, Studio E was launched to offer group art therapy sessions as an outlet of expression for people with epilepsy. In celebration of artwork created during [...]

Vascular risk linked to long-term antiepileptic drug therapy
Published on November 15, 2011

New research reveals that patients with epilepsy who were treated for extended periods with older generation antiepileptic drugs (AEDs) may be at increased risk for developing atherosclerosis, a common disorder known as hardening of the arteries. According to the findings now available in Epilepsia, the journal of the International League Against Epilepsy (ILAE), the vascular risk [...]

Brain Stimulator Shown to Reduce ‘Untreatable’ Epileptic Seizures
Published on November 9, 2011

Brain stimulation, already approved by the U.S. Food and Drug Administration for the treatment of Parkinson’s disease and essential tremor, has now been shown to offer significant relief to patients with intractable seizures for whom drugs and other treatments have not worked. Read more…

Abbott Said to Agree to Pay $1.3 Billion for Depakote Suits
Published on October 26, 2011

Abbott Laboratories agreed to pay at least $1.3 billion to settle claims by the U.S. government and 24 states alleging the company illegally marketed its Depakote epilepsy drug, people familiar with the accords said. Read more…

FDA approves Onfi to treat severe type of seizures
Published on October 24, 2011

On Oct. 21, the U.S. Food and Drug Administration approved Onfi tablets (clobazam) for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome in adults and children 2 years of age and older. As Onfi is intended to treat a disease or condition that affects fewer than 200,000 people in the United [...]